Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  American Journal of Hypertension

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0895-7061(00)01177-8PMID 11206684
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of sildenafil citrate on human hemodynamics.

  1999cited by this paper
• Erectile dysfunction and sildenafil citrate and cardiologists.

  1999cited by this paper
• Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist.

  1999cited by this paper
• Erectile dysfunction and sildenafil citrate and cardiologists.

  1999cited by this paper
• Clinical safety of oral sildenafil citrate (VIAGRATM) in the treatment of erectile dysfunction

  1998cited by this paper
• Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group.

  1998cited by this paper
• The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction.

  1997cited by this paper
• Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study.

  1994cited by this paper
• Sexual dysfunction with antihypertensive drugs.

  1994cited by this paper

• Flat magnetic stimulation technology: a promising therapy for erectile dysfunction management.

  2025cites this paper
• Novel pharmacological approaches to lowering blood pressure and managing hypertension

  2025cites this paper
• Drug-Drug Interactions in the Management of Patients With Pulmonary Arterial Hypertension

  2022cites this paper
• Update of the position paper on arterial hypertension and erectile dysfunction.

  2020cites this paper
• Construction of New Coated Carbon Electrodes for Determination of Sildenafil Citrate Drug

  2020cites this paper
• Repurposing of the PDE5 inhibitor sildenafil for treatment of persistent pulmonary hypertension in neonates.

  2020cites this paper
• Effects of chronic type 5 phosphodiesterase inhibition on penile microvascular reactivity in hypertensive patients with erectile dysfunction: a randomized crossover placebo-controlled trial

  2020cites this paper
• An Evaluation of a Clinical Care Pathway for the Management of Men With Nonorganic Erectile Dysfunction.

  2019cites this paper
• New Modified Electrodes of Graphite paste with Nano Silicon dioxide For Determination of Sildenafil citrate Drug

  2019cites this paper
• Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease

  2019cites this paper
• Cœur et sexe, quoi de neuf ?

  2018cites this paper
• Pharmacotherapy for erectile dysfunction in diabetic males

  2018cites this paper
• Erectile Dysfunction: AUA Guideline

  2018cites this paper
• Treatment of Erectile Disorder

  2017cites this paper
• Phosphodiesterase-5 Inhibitors: Raynaud's and Beyond

  2017cites this paper
• Evaluation and Management of Erectile Dysfunction in the Hypertensive Patient

  2017cites this paper
• Disfunción sexual y calidad de vida según el tipo de tratamiento renal sustitutivo

  2016cites this paper
• Chapter 13 – Sexual Function and Intimacy

  2016cites this paper
• Effects of mirodenafil on the hemodynamics in hypertensive patients taking amlodipine

  2016cites this paper
• A review of the efficacy and safety of mirodenafil in the management of erectile dysfunction

  2016cites this paper
• [Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension].

  2015cites this paper
• Misconceptions and facts about treating hypertension.

  2015cites this paper
• Udenafil for the treatment of erectile dysfunction

  2014cites this paper
• Management of erectile dysfunction in hypertension: Tips and tricks.

  2014cites this paper
• ISCHEMIC HEART DISEASE ( D MUKHERJEE , SECTION EDITOR ) Sexual Activity and Ischemic Heart Disease

  2014cites this paper
• Role of Phosphodiesterase-5 Inhibitors in Heart Failure: Emerging Data and Concepts

  2013cites this paper
• Erectile dysfunction diagnosis and treatment as a means to improve medication adherence and optimize comorbidity management.

  2013cites this paper
• Effectiveness and Safety of Phosphodiesterase 5 Inhibitors in Patients with Cardiovascular Disease and Hypertension

  2013cites this paper
• Potent natural aphrodisiacs for the management of erectile dysfunction and male sexual debilities.

  2012cites this paper
• The Pleiotropic Effects of Phosphodiesterase 5 Inhibitors on Function and Safety in Patients With Cardiovascular Disease and Hypertension

  2012cites this paper
• New Treatment Options for Erectile Dysfunction in Patients with Diabetes Mellitus

  2012cites this paper
• Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association.

  2012cites this paper
• Sexual Activity and Cardiovascular Disease : A Scientific Statement From the American

  2012cites this paper
• Drug discovery in the next decade: innovation needed ASAP.

  2012cites this paper
• Sexual Activity and Cardiovascular Disease : A Scientific Statement From the

  2012cites this paper
• Treatment of High Blood Pressure Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and

  2012cites this paper
• for Chapter 11 Diuretic Therapy in Cardiovascular Disease

  2011cites this paper
• Erectile Dysfunction and Cardiovascular Disease

  2011cites this paper
• Drug discovery in the next decade: innovation needed ASAP.

  2011cites this paper
• Evaluation of sexual function in hypertensive men receiving treatment: a review of current guidelines recommendation.

  2011cites this paper
• Drug Interactions With Phosphodiesterase-5 Inhibitors Used for the Treatment of Erectile Dysfunction or Pulmonary Hypertension

  2010cites this paper
• Disorders of Erection, Cohabitation, and Ejaculation

  2010cites this paper
• Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial.

  2010cites this paper
• Efficacy and safety of mirodenafil in men taking antihypertensive medications.

  2010cites this paper
• Safety and efficacy of sildenafil citrate in treating erectile dysfunction in patients with combat‐related post‐traumatic stress disorder: a double‐blind, randomized and placebo‐controlled study

  2009cites this paper
• Hypertension and sexual dysfunction

  2009cites this paper
• Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions.

  2009cites this paper
• Störungen der Erektion, Kohabitation und Ejakulation

  2009cites this paper
• Evaluation, and Treatment of High Blood Pressure Seventh Report of the Joint National Committee on Prevention, Detection,

  2008cites this paper
• Phosphodiesterase 5 inhibition in essential hypertension

  2008cites this paper
• Effects of phosphodiesterase-5 inhibitors on sperm parameters and fertilizing capacity.

  2008cites this paper
• An open-label, multicenter, flexible dose study to evaluate the efficacy and safety of Viagra (sildenafil citrate) in Korean men with erectile dysfunction and arterial hypertension who are taking antihypertensive agents.

  2008cites this paper
• Phosphodiesterase type 5 inhibitors: safety and adverse events

  2008cites this paper
• Chapter 51 – Diuretics and β-Blockers

  2008cites this paper
• Sexual dysfunction: the ‘prima ballerina’ of hypertension-related quality-of-life complications

  2008cites this paper
• Efficacy of vardenafil for the treatment of erectile dysfunction in men with hypertension:a meta-analysis of clinical trial data

  2007cites this paper
• Chronic sildenafil in men with diabetes and erectile dysfunction

  2007cites this paper
• Sildenafil is well tolerated by erectile dysfunction patients taking antihypertensive medications, including those on multidrug regimens.

  2007cites this paper
• Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors

  2007cites this paper
• Functional and morphological improvement in erectile tissue of hypertensive rats by long-term combined therapy with phosphodiesterase type 5 inhibitor and losartan.

  2007cites this paper
• Erectile dysfunction and hypertension

  2007cites this paper
• Analysis of the efficacy and safety of sildenafil citrate in the geriatric population

  2007cites this paper
• Neue Indikationen für Phosphodiesterase-5-Inhibitoren

  2007cites this paper
• Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?

  2007cites this paper
• Type 5 Phosphodiesterase Inhibitors in the Treatment of Erectile Dysfunction and Cardiovascular Disease

  2007cites this paper
• Sexual sequelae of general medical disorders.

  2007cites this paper
• SOUČASNÉ MOŽNOSTI FARMAKOLOGICKÉ SOUČASNÉ MOŽNOSTI FARMAKOLOGICKÉ LÉČBY EREKTILNÍ DYSFUNKCE LÉČBY EREKTILNÍ DYSFUNKCE

  2007cites this paper
• Phosphodiesterase 5: Molecular Characteristics Relating to Structure, Function, and Regulation

  2006cites this paper
• The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine.

  2006cites this paper
• Cardiovascular safety of sildenafil citrate (Viagra): an updated perspective.

  2006cites this paper
• Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease.

  2006cites this paper
• Sexual function in hypertensive patients receiving treatment

  2006cites this paper
• Management of the Cardinal Features of Andropause

  2006cites this paper
• Phosphodiesterase type 5 inhibitor sildenafil citrate does not potentiate the vasodilative properties of nebivolol in rat aorta.

  2006cites this paper
• Sexual Dysfunction in Essential Hypertension: Myth or Reality?

  2006cites this paper
• Tyrosine-612 in PDE5 contributes to higher affinity for vardenafil over sildenafil

  2006cites this paper
• Cardiovascular risk factors determine erectile and arterial function response to sildenafil.

  2006cites this paper
• Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference).

  2006cites this paper
• Treatment of pulmonary arterial hypertension with sildenafil: from pathophysiology to clinical evidence.

  2006cites this paper
• Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004).

  2006cites this paper
• Phosphodiesterase-5 inhibitors and their hemodynamic effects

  2006cites this paper
• Tyrosine-612 in PDE5 contributes to higher affinity for vardenafil over sildenafil

  2006cites this paper
• Hypertension and Erectile Dysfunction

  2006cites this paper
• Erectile dysfunction in the aging man: current options for treatment

  2006cites this paper
• Cardiac Issues Related to Erectile Dysfunction

  2006cites this paper
• Erectile dysfunction

  2006cites this paper
• Hypertension, Antihypertensive Therapy, and Erectile Dysfunction

  2006cites this paper
• Effects of Combined Treatment with Sildenafil and Itraconazole on the Cardiovascular System in Telemetered Conscious Dogs

  2005cites this paper
• Hipertensión arterial, medicación antihipertensiva y disfunción eréctil: una perspectiva basada en la evidencia

  2005cites this paper
• Efficacy, safety and tolerability of sildenafil in Brazilian hypertensive patients on multiple antihypertensive drugs.

  2005cites this paper
• The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease.

  2005cites this paper
• Past, present, and future: a 7‐year update of Viagra® (sildenafil citrate)

  2005cites this paper
• Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development

  2005cites this paper
• Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction

  2005cites this paper
• Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety

  2005cites this paper
• Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives.

  2005cites this paper
• A case of erectile dysfunction and risk factors for coronary artery disease

  2005cites this paper
• Sildenafil: efficacy, safety, tolerability and mechanism of action in treating erectile dysfunction

  2005cites this paper
• Hemodynamic effects of sildenafil citrate and isosorbide mononitrate in men with coronary artery disease and erectile dysfunction.

  2005cites this paper
• Acute Myocardial Infarction After Sildenafil Citrate Ingestion

  2005cites this paper